Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the six-month period from November 1, 2015, to April 30, 2016. The report, dated May 11, 2016, serves as a Block Listing Six Monthly Return detailing the status of various share option and savings-related share schemes.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the number of securities allotted and unallotted under specific employee share schemes.
Material Changes in Share Schemes
The following changes in unallotted securities were reported for the period:
- GlaxoSmithKline Share Option Plan - Ordinary Shares: Decreased by 1,001,663 shares (issued/allotted), leaving a balance of 7,398,066.
- GlaxoSmithKline Share Option Plan - ADS: Decreased by 502,980 shares (issued/allotted), leaving a balance of 9,883,088.
- GlaxoSmithKline plc Sharesave Plan 2012: Decreased by 3,109,531 shares (issued/allotted), leaving a balance of 494,191.
- Other Schemes: No securities were issued or allotted during the period for the Glaxo Wellcome UK, Glaxo Wellcome International, Glaxo Wellcome 1999, SmithKline Beecham 1989 (Approved/Unapproved), and GlaxoSmithKline Savings Related Share Option Scheme. Balances remained unchanged from the previous return.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a statutory return regarding share scheme administration.
Investor Verification Points
- Verify the total number of shares issued under the Sharesave Plan 2012 (3,109,531) against the company's broader equity compensation expense reporting.
- Confirm the remaining pool of unallotted shares across all schemes to assess future dilution potential.
- Note that no new shares were added to any scheme block during this six-month period.